Want to see ALDX full AI Analyst Report?
ALDX Stock Chart & Stats
$1.55
$0.06(4.28%)
At close: 4:00 PM EDT
$1.55
$0.06(4.28%)
Day’s Range― - ―
52-Week Range$1.07 - $5.93
Previous Close$1.61
Volume1.23M
Average Volume (3M)683.28K
Market Cap
$80.84M
Enterprise Value$83.54
Total Cash (Recent Filing)$45.09M
Total Debt (Recent Filing)$143.45K
Price to Earnings (P/E)―
Beta2.95
Next Earnings
May 06, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding60,326,420
10 Day Avg. Volume460,180
30 Day Avg. Volume683,284
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)7.03
Price to Sales (P/S)0.00
P/FCF Ratio-9.33
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.00Price Target Upside29.03% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$1.25M
Bulls Say, Bears Say
Bulls Say
Manageable LeverageModest debt relative to equity provides some financial flexibility and reduces the burden of interest obligations while the company funds development. Although losses remain significant, restrained leverage may help preserve strategic options compared with a similarly unprofitable biotech carrying heavier debt.
2025 Loss ImprovementThe reduction in losses during 2025 indicates some improvement in cost or spending discipline, even though Aldeyra remains unprofitable and pre-revenue. If sustained, narrower losses could extend financial runway and make future development spending more efficient over the next several quarters.
Multi-Year Headquarters CommitmentA multi-year headquarters lease supports operational continuity and indicates the company has established a defined base for its ongoing corporate and development activities. This is not a commercialization milestone, but it may provide organizational stability as the pipeline advances through clinical development.
Bears Say
No Demonstrated RevenueThe absence of reported revenue means Aldeyra has not yet demonstrated commercial demand or an internally generated funding base. Continued dependence on development progress and external financing leaves the business exposed to prolonged pre-revenue execution risk over the next several quarters.
Persistent Cash BurnPersistent negative operating and free cash flow shows that Aldeyra cannot currently fund operations from internally generated cash. The sharp TTM deterioration suggests renewed spending intensity, increasing pressure to manage development costs and secure additional funding as programs progress.
Recurring Operating LossesRecurring operating and net losses demonstrate that the current business model has not reached sustainable profitability. Negative returns on equity also indicate ongoing value erosion, limiting the company’s ability to compound capital internally and increasing reliance on successful pipeline execution.
Aldeyra Therapeutics News
ALDX FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was $1.07 and its highest was $5.93 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is $80.84M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
Aldeyra Therapeutics’s upcoming earnings report date is May 06, 2027 which is in 235 days.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on Jul 31, 2026. The company reported -$0.09 earnings per share for the quarter.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 60,326,420 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -$0.09 in its last earnings report. Following the earnings report the stock price went down -3.75%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Currently, no hedge funds are holding shares in ALDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aldeyra Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (29.03% Upside)
$2.00 (29.03% Upside)
Blogger Sentiment
Bullish
ALDX Sentiment 100%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Increased
By 17.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-44.05%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
ALDX Stock 12 Month Forecast
Average Price Target
$2.00
▲(29.03% Upside)
Technical Analysis
Omeros
―
Galectin Therapeutics
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.29% Insiders
8.73% Mutual Funds
20.19% Other Institutional Investors
62.73% Public Companies and
Individual Investors